HARC Center: HIV Accessory and Regulatory Complexes
Project Number5P50AI150476-14
Former Number5P50GM082250-13
Contact PI/Project LeaderKROGAN, NEVAN J
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
CENTERS FOR HIV/AIDS-RELATED STRUCTURAL BIOLOGY (P50)
HARC CENTER: HIV ACCESSORY AND REGULATORY COMPLEXES
OVERALL SUMMARY
The HARC Center is an integrated program proposed by investigators whose overarching goal is to improve
understanding of the interactions between HIV accessory and regulatory proteins and host cellular systems to
enable eventual expansion of therapeutic approaches. There are currently no HIV therapeutics targeting any
of the proteins on which the HARC Center is focused (HIV-1 Vif, Vpu, Nef, Tat and Rev proteins and their
interacting viral and cellular partners). The scientific focus of the Center is on determining structures of these
complexes, using an integrated Systems to Structure pipeline that includes (1) Discovery, through novel
methods of functional proteomics and genetics being developed in the HARC Center, (2) Validation through
breakthrough CRISPR methods in primary T cells as well as targeted in vivo and in vitro functional assays, and
(3) Structure Determination using a synthesis of innovative structural techniques developed in the HARC
Center to address the large, flexible, heterogeneous and sometimes membrane-associated systems we study.
We are focused on two themes aimed at understanding the biological questions surrounding HIV replication
and persistence in the host cell. These include how the virus counteracts host restriction mechanisms (Theme
1: “Counteracting”) and how the virus hijacks host systems for viral transcription and RNA export/trafficking
to ensure continuation of the viral life cycle (Theme 2: “Hijacking”). The seven projects proposed here
include: (1) Structure and Evolution of APOBEC3-Vif Interactions, (2) Regulation of Vif and Rewiring of Host
Pathways, (3) The Multiple Functions of Vpu at the Membrane, (4) Nef Interaction Networks at the Membrane,
(5) Tat-Host Transcription Complexes, (6) Structure and Dynamics of Rev and RNA-Host Complexes, and (7)
Characterization of “Super Restriction Factors” and Prediction of Host-HIV Interfaces. The HARC Center
projects are supported by an administrative core and seven technology cores essential for their completion: (1)
Proteomic Approaches to HIV Function, (2) CRISPR in Primary Cells to Study HIV-Host Function, (3)
Molecular Imaging Using Cryo-Electron Microscopy (EM), (4) Application and Development of Antibody Tools,
(5) Integrative Modeling of HIV-Human Complexes, (6) X-ray Screening and Rapid Structure Determination,
and (7) Membrane Protein Expression/Purification.
We are committed to collaborating with Sister Centers and the HIV research community as well as training the
next generation of investigators. We create and support opportunities including the Technology Training
Residency to bring young investigators to learn in our Center's Cores, and we seed new research through the
Collaborative Opportunity Fund, along with holding events such as seminars and an annual symposium.
Public Health Relevance Statement
The HARC Center mission is to elucidate the molecular basis of systems that are essential for, or contribute to,
the pathogenesis of HIV/AIDS, including the physical/functional interactions that occur between viral and
human proteins, membranes, lipids and nucleic acids (DNA/RNA). None of the HIV accessory or regulatory
proteins are currently targeted by anti-viral therapeutics, and so better molecular understanding of their
functions and mechanisms may reveal new therapeutic strategies for intervention, including strategies that may
escape the limitations of current drug regimens where mutations in the targeted HIV enzymes can diminish
drug efficacy. Through our powerful structure/function pipeline, now expanded to include CRISPR technology
and other genetic approaches, we can gain unprecedented insight into HIV biology, new avenues to complex
structures, and the potential to fundamentally alter treatment strategies by targeting key cellular processes that
contribute to AIDS at interfaces where mutational resistance is highly unlikely.
National Institute of Allergy and Infectious Diseases
CFDA Code
859
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
27-August-2007
Project End Date
31-August-2022
Budget Start Date
01-September-2020
Budget End Date
31-August-2021
Project Funding Information for 2020
Total Funding
$4,812,427
Direct Costs
$3,778,437
Indirect Costs
$1,567,436
Year
Funding IC
FY Total Cost by IC
2020
National Institute of Allergy and Infectious Diseases
$4,812,427
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5P50AI150476-14
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P50AI150476-14
Patents
No Patents information available for 5P50AI150476-14
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P50AI150476-14
Clinical Studies
No Clinical Studies information available for 5P50AI150476-14
News and More
Related News Releases
No news release information available for 5P50AI150476-14
History
No Historical information available for 5P50AI150476-14
Similar Projects
No Similar Projects information available for 5P50AI150476-14